All Topics

June 28, 2024 | Controlled Substances, Fetal and Infant Health, Legal & Legislative Research, Maternal Health, Opioids, Prescription Drugs, Substance Misuse, Treatments

In this document, the Legislative Analysis and Public Policy Association (LAPPA) examines state-level statutes and regulations related to substance use during pregnancy and whether such use during pregnancy is considered child abuse or neglect in the jurisdiction. ...

June 12, 2024 | Case Law Monitor

Each issue of Case Law Monitor highlights unique cases from around the United States in the areas of public health and safety, substance use disorder, and the criminal justice system. Every other month, LAPPA updates readers on cases that are important to the field....

May 22, 2024 | Medication Assisted Treatment (MAT), Model Laws, Pharmacy, Recovery, Treatments

Drafted in collaboration with the Center for Health Law Studies at the St. Louis University School of Law, the Model Pharmacist Collaboration for Medication for Opioid Use Disorder Act can help to save the lives and improve the health and quality of life of individuals who have an opioid use disorder (OUD) by expanding access to and availability of medication for OUD. This Act does so by increasing the health care workforce that provides medication for OUD by authorizing pharmacists to: (1) prescribe medications for OUD for treatment and refer patients for long-term treatment; and (2) prescribe, initiate, monitor, and adjust long-term treatment pursuant to collaborative practice agreements for collaborative drug therapy management. The Act further requires Medicaid and private health insurance coverage for pharmacists’ comprehensive patient care and medication management services provided as part of a standing protocol or drug therapy management collaborative practice for medication for OUD. It also provides for the establishment of a grant program to incentivize and sustain inter-professional collaborations that include pharmacists through educational programs, statewide initiatives, community programs, and pilot programs....

May 15, 2024 | News Bites

Each issue of News Bites highlights unique news articles from around the United States in the areas of public health and safety, substance use disorder, and the criminal justice system. Every other month, LAPPA updates readers on news they may have missed....

May 12, 2024 | Emergency Departments, First Responders, Harm Reduction, Innovative Initiatives, Medication Assisted Treatment (MAT), Opioid Antagonists, Opioid Antagonists, Opioids, Public Health, Recovery, Substance Misuse, Treatments

Paramedics in the State of New Jersey are permitted to carry and administer buprenorphine to treat acute withdrawal symptoms after having had an opioid overdose reversed with naloxone. The directive, via Executive Order from the State Health Commissioner, simply added buprenorphine to the list of medications available to paramedics in the MICUs and required officials in each county to train paramedics on the protocol. ...

April 18, 2024 | Case Law Monitor

Each issue of Case Law Monitor highlights unique cases from around the United States in the areas of public health and safety, substance use disorder, and the criminal justice system. Every other month, LAPPA updates readers on cases that are important to the field....

April 11, 2024 | Controlled Substances, Criminal Justice, Harm Reduction, Medication Assisted Treatment (MAT), Naloxone, Opioid Antagonists, Opioids, Prescription Drugs, Public Health, Public Safety, Recovery, Reports & Studies, Substance Misuse, Treatments

The Addiction and Public Policy Initiative at the O’Neill Institute for National and Global Health Law was established in 2018 through a generous grant from Arnold Ventures. Housed at Georgetown Law, the Addiction and Public Policy Initiative works at the intersection of public health and the law to advance a public health approach to substance use disorder and the overdose epidemic through legal and policy strategies that promote evidence-based treatment, harm reduction, and recovery. This reports highlights O'Neill's accomplishments over the last five years....

April 9, 2024 | Emergency Departments, First Responders, Innovative Initiatives, Medication Assisted Treatment (MAT), Opioids, Public Health, Recovery, Substance Misuse, Treatments

The Coordinated Opioid Recovery (CORE) Network, overseen by the Florida Department of Health, the Florida Department of Children and Families, and the Florida Agency for Health Care Administration establishes a system of care for individuals suffering from substance use disorder (SUD). CORE provides a state-supported, coordinated system of addiction care for individuals with SUD and has provided approximately 550,000 services to support patients since its inception in 2022....

March 26, 2024 | Controlled Substances, Fact Sheets, Opioids, Prescription Drugs, Public Health, Public Safety

The first U.S. reports of counterfeit pills containing fentanyl emerged in a handful of jurisdictions in 2015 and by October 2019, all U.S. jurisdictions reported them. One reason for the proliferation is the ease with which drug traffickers can enter this market. With only a few thousand dollars, a person can purchase a pill press, pill molds, and dies that mimic trademarked pharmaceuticals and enough illicitly imported fentanyl to generate $5 to $20 million in sellable counterfeit pills. Given the simple manufacturing process and low startup costs, counterfeiting is an attractive area for drug traffickers, albeit one that creates substantial health risks to consumers. Despite this, however, there are relatively few federal or state laws governing access to pill press machines, and those that exist do not provide for substantial oversight or assessment. In this fact sheet, the Legislative Analysis and Public Policy Association reviews: (1) what pill presses are and how people obtain them; (2) why fentanyl is an often-used drug in counterfeit pills and the health concerns this poses; and (3) the limited, currently-in-force, applicable state and federal laws....

March 18, 2024 | Fact Sheets, Novel Psychoactive Substances, Opioids, Public Safety, Stimulants, Substance Misuse, Synthetic Drugs

The Legislative Analysis and Public Policy Association (LAPPA) is monitoring the emergence of novel psychoactive substances (NPS) appearing on the streets of the United States. This fact sheet, which focuses on Xylazine, was originally the second in a series that highlights these dangerous drugs. This is an update to the original version....